Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of β-blocker therapy in patients with dilated cardiomyopathy

European Journal of Nuclear Medicine

Volumn 24, Issue 5, 1997, Pages 523-529

  Fukuoka, Shuji ^a   Hayashida, Kohei ^a   Hirose, Yoshiaki ^a   Shimotsu, Yoriko ^a   Ishida, Yoshio ^a   Kakuchi, Hiroyuki ^a   Eto, Tanenao ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Bull's eye map; Dilated cardiomyopathy; Drug effectiveness; Iodine 123 metaiodobenzylguanidine; blocker therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; FEMALE; HEART DILATATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HUMAN; MALE; MEDIASTINUM; PREDICTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030928273     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01267684     Document Type: Article

References (29)

1. Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.
2. Hjalmarson A, Waagstein F. New therapeutic strategies in chronic heart failure: challenge of long-term beta-blockade. Eur Heart J 1991; 12 Suppl F: 63-69.
3. Gilbert EM, Mestroni L, Anderson JL, et al. Can response to beta-blocker therapy in idiopathic dilated cardiomyopathy be predicted by baseline parameters? Circulation 1989; 80 Suppl II: II-428.
4. Sisson JC, Wieland DM, Sherman P, et al. Meta-iodobenzyl-guanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987; 28: 1620-1624.
5. Mitrani RD, Klein LS, Miles MW, et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 1993; 22: 1344-1353.
6. 123I]meta-iodobenzyl-guanidine scans in patients with ventricular tachycardia and a "clinically normal" heart. Br Heart J 1993; 69: 6-13.
7. Yamakado K, Takeda K, Kitano T, et al. Serial change of iodine-123 metaiodobenzylguanidine (MIBG) myocardial concentration in patients with dilated cardiomyopathy. Eur J Nucl Med 1992; 19: 265-270.
8. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12: 1252-1258.
9. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192-1199.
10. Dae MW, De Marco T, Botvinick EH, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts: implications for clinical studies. J Nucl Med 1992; 33: 1444-1450.
11. Dae MW, Botvinick E, O'Connell J, et al. Regional myocardial MIBG washout parallels regional sympathetic innervation [abstract]. J Nucl Med 1987; 28: 608.
12. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990; 82: 473-483.
13. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-1100.
14. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-reponse of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994; 89: 1632-1642.
15. Sahn DJ, DeMaria A, Kisslo J, et al. The committee on M-mode standardization of the American Society of Echocardiography: results of a survey of echocardiography measurements. Circulation 1978; 58: 1072-1083.
16. Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis 1974; 17: 125-149.
17. Gilbert EM, Olsen SL, Mealey P, et al. Is β-receptor up-regulation necessary for improved LV function in dilated cardiomyopathy [abstract]? Circulation 1991; 84 Suppl II: II-468.
18. Eichhorn EJ. The paradox of β-adrenergic blockade for the management of congestive heart failure. Am J Med 1992; 92: 527-538.
19. Alderman J, Grossman W. Are β-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? Circulation 1985; 71: 854-857.
20. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure: reversal of sympathetic-induced alterations of immunologic function. Circulation 1994; 90: 1774-1780.
21. Eichhorn E. Do β-blockers have a role in patients with congestive heart failure? Cardiol Clin 1994; 12: 133-142.
22. Swedberg K, Waagstein F, Hjalmarson A, et al. Prolongation of survival in congestive cardiomyopathy by beta receptor blockade. Lancet 1979; I: 1374-1376.
23. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
24. Waagstein F, Bristow MR, Swedberg K, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
25. Nakajo M, Shimabukuro K, Yoshimura H, et al. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986; 27: 84-89.
26. Kurata C, Wakabayashi Y, Shouda S, et al. Enhanced cardiac clearance of iodine-123-MIBG in chronic renal failure. J Nucl Med 1995; 36: 2037-2043.
27. Meredith IT, Eisenhofer G, Lambert GW, et al. Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993; 88: 136-145.
28. Schomig A. Catecholamines in myocardial ischemia: systemic and cardiac release. Circulation 1990; 82 Suppl II: II-13-II-22.
29. Thames MD, Klopfenstein HS, Abbound FM, et al. Preferential distribution of inhibitory cardiac receptors with vagal afferents to the inferoposterior wall of the left ventricle activated during coronary occlusion in the dog. Circ Res 1978; 43: 512-519.